HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/18/2012 -- Navidea Biopharma (AMEX:NAVB) is +0.27 - +9.57% from the previous close of $2.82. It traded between $2.78 - 3.115 with total traded volume of 2319994 shares. Keep a close eye on NAVB, as the stock has been showing unusual moves over the past weeks. At Current market price, NAVB has recovered +50.73% from its 52-week Low of 2.05 and has Pulled back -35.22% from its 52-week high of 4.77. Shares of Navidea Biopharmaceuticals (NASDAQ:NAVB) are trading up 9% Monday on optimism over a quick resubmission of information in support of Lymphoseek's approval following a Complete Response Letter (CRL) from the FDA last week. Optimism is being fueled by insider buying, an indication that a quick turnaround and approval of Lymphoseek is plausible, as the company indicated in its conference call after the recent FDA decision.
Can NAVB Continue To Move Higher? Find Out Here
InterMune, Inc. (NasdaqNM:ITMN) is +0.73 - +8.11% from the previous close of $9.00. It traded between $8.855 - 9.73 with total traded volume of 2370482 shares. Keep a close eye on ITMN, as the stock has been showing unusual moves over the past weeks. At Current market price, ITMN has recovered +34.95% from its 52-week Low of 7.21 and has Pulled back -64.27% from its 52-week high of 27.23. InterMune Inc. (ITMN), a biotechnology company based in Brisbane, California, sells Esbriet in the European Union and is in late-stage trials in the U.S. The results published today “will encourage patients and frustrate them because thalidomide is not FDA-approved for this indication and they’re not going to be able to get this,” Horton said. “My goal is to gain enough interest” to do further studies, she said.
Can ITMN Continue To Move Higher? Find Out Here
Tesla Motors, Inc (NasdaqNM:TSLA) reported EPS of -3.268. For the Current Fiscal year, the company is expected to report EPS of -2.66. For the Next Quarter and Next Year, the company is expected to report EPS of -0.19 and 0.46 respectively. At Current Market Price, TSLA is in distance of +12.47% from its 50-day Moving Average price of $28.9326 and +3.45% from its 200-day Moving Average price of $31.454. The ultra-luxury electric-car maker has recently ramped up production to 100 vehicles per week. This is ahead of schedule, but it remains far short of CEO Elon Musk's goal of more than 400 vehicles per week by 2013. On Monday, analysts at Morgan Stanley wrote that "we think fears over a slower ramp are overdone" and upgraded the company's price target for shares of Tesla from $45 to $50. Shares currently trade around $32, representing more than 50% upside to Morgan Stanley's estimate.
Can TSLA Continue To Move Higher? Find Out Here
Gilead Sciences, (NasdaqNM:GILD) reported EPS of 3.301. For the Current Fiscal year, the company is expected to report EPS of 3.78. For the Next Quarter and Next Year, the company is expected to report EPS of 0.95 and 4.38 respectively. At Current Market Price, GILD is in distance of +13.90% from its 50-day Moving Average price of $57.7689 and +27.26% from its 200-day Moving Average price of $51.7068. Shares of anti-viral drug developer Gilead Sciences Inc. (GILD, $65.80, +$3.78, +6.09%) rose Monday after analysts lifted their price targets. J.P. Morgan analyst Geoff Meacham raised his target to $75 from $70, citing enthusiasm over the company's new HIV medication Stribild and hepatitis C drug program. On Friday, Deutsche Bank analyst Robyn Karnauskas raised her price target to $68 a share from $65.
Can GILD Continue To Move Higher? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)